Knoa Pharma Launches as Public Health-Focused Company Aiming to Support Patients and Combat the Opioid Crisis
Knoa Pharma LLC has officially launched as a newly established independent organization with a mission centered on improving public health, ensuring responsible access to essential medicines, and contributing meaningfully to efforts aimed at addressing the opioid crisis in the United States. The company’s formation follows the conclusion of Chapter 11 proceedings involving Purdue Pharma LP on May 1, 2026, marking the end of Purdue’s operations and the beginning of a restructured, purpose-driven entity designed to operate under a fundamentally different model.
A New Model for Pharmaceutical Governance
Knoa Pharma has been created through a collaborative process involving a wide array of stakeholders, including federal and state authorities, personal injury claimants, and other affected parties. Among these, the United States Department of Justice played a central role in shaping the framework that governs the new organization. The result is a company designed with strong oversight mechanisms, transparent accountability structures, and a clear mandate to serve the public good.
Unlike traditional pharmaceutical companies, Knoa Pharma is wholly owned by a not-for-profit entity, the Knoa Foundation, which is structured as a 501(c)(4) organization. This ownership model is intended to ensure that the company’s operations and financial outcomes are aligned with broader societal and public health objectives rather than purely commercial interests.
To reinforce this mission, Knoa Pharma operates under the guidance of two independent governing bodies: the Board of Trustees of the Knoa Foundation and the Board of Directors of Knoa Pharma. Importantly, all members of these boards have no prior affiliation with Purdue Pharma, a measure designed to ensure independence, credibility, and a fresh approach to governance.
Dual-Board Oversight Structure
The Knoa Foundation Board of Trustees includes prominent figures in medicine, public health policy, and philanthropy. Among them is Paul B Rothman, former CEO of Johns Hopkins Medicine and a member of the National Academy of Medicine, who serves as Board Chair. He is joined by Rahul Gupta, a former Director of the White House Office of National Drug Control Policy, and David Saltzman, a co-founder of the Robin Hood Foundation and a leader in health equity initiatives.
Complementing this group is the Knoa Pharma Board of Directors, chaired by Norbert Riedel, a seasoned biopharmaceutical executive with decades of experience in drug development and corporate leadership. Other board members bring expertise across compliance, governance, finance, and operations, ensuring that the company is managed with a high degree of professionalism and accountability.
Together, these two governing bodies are tasked with ensuring that Knoa Pharma operates responsibly, ethically, and in alignment with its public health mission.
Core Business and Operating Principles
As a pharmaceutical manufacturer, Knoa Pharma will continue to produce a range of existing medicines, including opioid analgesics, which remain essential for certain patient populations when used appropriately. However, the company has committed to a strict policy of not promoting opioid products, distinguishing its approach from historical industry practices.
Operations are conducted under a legally binding injunction, with oversight from an independent monitor. This framework is designed to ensure that all activities related to opioid production and distribution are carried out in a manner that prioritizes patient safety and minimizes the risk of misuse or diversion.
In addition to maintaining its existing portfolio, Knoa Pharma plans to continue developing both branded and generic medicines to address a variety of medical conditions. This balanced approach allows the company to meet ongoing patient needs while also contributing to innovation and access in other therapeutic areas.
Supporting Opioid Abatement and Public Health
A defining feature of Knoa Pharma’s model is its commitment to directing the value generated from its operations toward opioid abatement efforts. Revenues will be used to fund initiatives across the United States aimed at mitigating the impact of the opioid crisis, particularly in communities that have been disproportionately affected.
These efforts include the provision of overdose reversal agents and medications for opioid use disorder on a not-for-profit basis. By offering these critical treatments at or below the cost of production, Knoa Pharma seeks to remove financial barriers and expand access to life-saving care.
According to Paul Rothman, this approach ensures that the company’s resources are directly reinvested into public health initiatives. He emphasized that providing affordable access to treatments for opioid overdose and addiction is central to the company’s mission and a key component of its long-term strategy.
Leadership Perspective and Strategic Vision
From an operational standpoint, Knoa Pharma’s leadership has emphasized the importance of building a sustainable and accountable organization. Norbert Riedel highlighted that the company launches with a strong foundation in scientific expertise and operational discipline, positioning it to deliver essential medicines safely and effectively.
He noted that the immediate priority is to establish a stable and transparent organization capable of meeting patient needs while fulfilling its broader public health mandate. This includes maintaining rigorous standards in manufacturing, compliance, and governance, as well as fostering trust among stakeholders and the public.
Interim Leadership Appointment
To guide the company through its initial phase, Marc Kesselman has been appointed as interim President and Chief Executive Officer. Kesselman brings extensive experience across government and corporate sectors, having previously served in roles within the Department of Justice, the White House, and as General Counsel of the U.S. Department of Agriculture.
His involvement in shaping Knoa Pharma’s structure and mission provides continuity as the company begins operations. A comprehensive search is underway to identify a permanent CEO who will lead the organization into its next phase of development.
Strengthening Clinical and Operational Capabilities
The broader leadership team and board composition reflect a deliberate effort to bring together expertise from multiple domains, including pharmaceuticals, compliance, human resources, and financial oversight. For example, board members such as Karen Griffin bring experience in global risk and compliance, while Patricia Lang contributes decades of leadership in human resources within healthcare and industrial organizations. Mike McHale, with a background in audit and financial advisory, adds further depth to the company’s governance capabilities.
This multidisciplinary approach is intended to ensure that Knoa Pharma operates with a high degree of rigor across all aspects of its business, from clinical development to financial management.
A Transformational Approach to Industry Responsibility
The launch of Knoa Pharma represents a significant departure from traditional pharmaceutical business models, particularly in the context of opioid manufacturing. By combining a not-for-profit ownership structure with strict regulatory oversight and a clear public health mission, the company aims to redefine how pharmaceutical organizations can contribute to addressing complex societal challenges.
Central to this approach is the idea that access to essential medicines must be balanced with responsibility and accountability. By eliminating promotional activities for opioids and focusing on safe distribution practices, Knoa Pharma seeks to reduce the risks associated with these medications while still ensuring they remain available for patients who need them.
As Knoa Pharma begins its operations, the company faces the dual challenge of maintaining a viable pharmaceutical business while fulfilling its public health commitments. Success will depend on its ability to execute effectively across manufacturing, compliance, and program implementation, while also building trust with patients, healthcare providers, and regulators.
The company’s unique structure and mission-driven focus position it as a potential model for how the pharmaceutical industry can evolve to better address public health priorities. By reinvesting its resources into opioid abatement and expanding access to critical treatments, Knoa Pharma aims to make a measurable impact on one of the most pressing health crises of our time.
The establishment of Knoa Pharma marks a pivotal moment in the intersection of healthcare, public policy, and corporate responsibility. Emerging from the restructuring of Purdue Pharma, the new organization is built on principles of transparency, accountability, and a commitment to the public good.
With strong governance, experienced leadership, and a clear mission, Knoa Pharma is poised to play a meaningful role in both delivering essential medicines and supporting efforts to combat the opioid crisis. Its progress in the coming years will be closely watched as an example of how innovative organizational models can contribute to improved health outcomes and societal well-being.
About Knoa Pharma LLC
Knoa Pharma makes important medicines safely and responsibly, while innovating to benefit patients and the public health. The company is dedicated to safely distributing medicines that are critical to patient care, enhancing its robust generics portfolio, addressing unmet medical needs, and supporting initiatives to address the opioid crisis.
Our public minded mission enables us to expand access to lifesaving overdose reversal medicines and affordable treatments for opioid use disorder – at no profit. Owned by a not-for-profit foundation, everything we do is centered on improving public health, saving lives, supporting recovery, and bringing forward medicines that make a meaningful difference.
Source Link:https://www.businesswire.com/
